Since we recently showed that drug-free patients with schizophrenia have lower levels of CB1R in the ACC, and that greater reductions were linked to greater cognitive deficits [41], we specifically aimed to investigate whether CB1R alterations in the ACC may be associated with glutamatergic alterations in the ACC in the same drug-free patients. The gene discussed is CNR1; the disease is schizophrenia.